MetaLead Secures CHF 1M to advance treatment for Wilson's disease

other

Summary

Zurich-based startup metaLead Therapeutics has raised CHF 1M from the UZH Life Sciences Fund to accelerate the development of a new treatment for Wilson disease, a rare condition caused by copper buildup in the body. The company is using a novel peptide-based platform to improve metal-binding therapies.

Classifications

industries
No industries detected
applications
No applications detected

AskAI Classifications

Labels
No AI classifications detected

Linked Companies